[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633554":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":12,"responsibleParty":31,"collaborators":35,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":12,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":12,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":12,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":12},{"fullName":5,"class":6},"Southeast University, China","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","Patients in the control group will receive standard comprehensive Western medical treatment.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Treatment Group","EXPERIMENTAL","Patients in the treatment group will receive Xuanbai Shengmai Decoction via oral administration or nasogastric feeding on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day divided into two administrations, for a total treatment duration of 7 days.",[18],"Drug: Xuanbai Shengmai Decoction",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Xuanbai Shengmai Decoction","Patients in the treatment group will receive Xuanbai Shengmai Decoction orally or via nasogastric gavage on the basis of standard comprehensive Western medical treatment.\n\nThe decoction will be administered within 24 hours after enrollment, one dose per day in two divided administrations, for a total of 7 days.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Airan Liu, PhD","CONTACT","+8615295557466","airanliu@126.com",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Ling Liu","Professor",[36,38,40,42,44,46],{"name":37,"class":6},"Beijing Hospital of Traditional Chinese Medicine",{"name":39,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":41,"class":6},"Jiangsu Province Hospital of Traditional Chinese Medicine",{"name":43,"class":6},"Subei People's Hospital of Jiangsu Province",{"name":45,"class":6},"Wuhan Hospital of Traditional Chinese Medicine",{"name":47,"class":48},"Shenzhen Hospital of Traditional Chinese Medicine","UNKNOWN","100633554","phase-3-study-of-xuanbai-shengmai-decoction-in-the-treatment-of-acute-respiratory-distress-syndrome-100633554",false,"NCT07528196","Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome","Clinical Collaboration Project of Integrated Traditional Chinese and Western Medicine for Major and Intractable Diseases - A Multicenter, Randomized Controlled Trial of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n1. Met the diagnostic criteria for ARDS according to the 2023 updated global definition.\n2. Within 48 hours of meeting the diagnostic criteria.\n3. Aged ≥ 18 years and ≤ 85 years.\n\nExclusion Criteria:\n\n1. Did not meet the diagnostic criteria.\n2. Pregnant or lactating women.\n3. Patients with gastrointestinal dysfunction (including gastrointestinal bleeding, severe intra-abdominal hypertension, severe intestinal obstruction, etc.), resulting in the inability to administer medication via nasogastric\u002Fnasoenteric tube or orally within 48 hours after enrollment.\n4. SOFA score \\> 13.\n5. Hypersensitivity to the study drugs.\n6. Withdrawal of treatment.","ALL","18 Years","85 Years",{"count":60,"type":61},308,"ESTIMATED","INTERVENTIONAL",[64],"PHASE3","Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and therapeutic efficacy in ARDS has become a hotspot.As characterized by syndrome differentiation, traditional Chinese medicine (TCM) treatment emphasizes interindividual heterogeneity and personalized management, which is expected to serve as a breakthrough in multi-target immune regulation for ARDS. The primary objective of the study is to investigate the effect of Xuanbai Shengmai Decoction on the prognosis of patients with ARDS in a prospective randomized controlled trial. The secondary objective is to evaluate the safety of Xuanbai Shengmai Decoction in the treatment of patients with ARDS.",[67],"Acute Respiratory Distress Syndrome (ARDS)",[67,69,22],"Traditional Chinese Medicine","NOT_YET_RECRUITING","2026-06-03",{"date":73,"type":74},"2026-06-05","ACTUAL",{"date":76,"type":61},"2026-08-20",{"date":78,"type":61},"2027-12",{"name":5,"class":6}]